Idera Pharmaceuticals Inc.

1.34-0.0100-0.74%Vol 5.65M1Y Perf -6.64%
Apr 9th, 2021 16:00 DELAYED
BID1.33 ASK1.34
Open1.33 Previous Close1.35
Pre-Market- After-Market1.35
 - -  0.01 0.75%
Target Price
1.50 
Analyst Rating
Strong Buy 1.00
Potential %
11.94 
Finscreener Ranking
★★★★+     56.37
Insiders Trans % 3/6/12 mo.
-75/-83/-83 
Value Ranking
★★★★★     62.36
Insiders Value % 3/6/12 mo.
-22/-72/-72 
Growth Ranking
★★★+     57.70
Insiders Shares Cnt. % 3/6/12 mo.
-46/-75/-75 
Income Ranking
 —    -
Market Cap56.62M 
Earnings Rating
Neutral
Price Range Ratio 52W %
2.44 
Earnings Date
29th Apr 2021

Today's Price Range

1.311.41

52W Range

1.226.14

5 Year PE Ratio Range

-4.30-1.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.52%
1 Month
-72.71%
3 Months
-68.69%
6 Months
-43.22%
1 Year
-6.64%
3 Years
-90.03%
5 Years
-91.23%
10 Years
-93.63%

TickerPriceChg.Chg.%
IDRA1.34-0.0100-0.74
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
5.40
5.90
-
0.00
-37 553.00
Leverage Ratio -0.70
ProfitabilityValueIndustryS&P 500US Markets
-
-4 034.70
-4 027.10
-4 880.70
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-40.82
35.11
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.23-0.218.70
Q03 2020-0.21-0.22-4.76
Q02 2020-0.36-0.2627.78
Q01 2020-0.40-0.43-7.50
Q04 2019--0.40-
Q03 2019-0.47-0.3917.02
Q02 2019-0.42-0.397.14
Q01 2019-0.46-0.4013.04
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.2167.19Positive
6/2021 QR-0.2060.78Positive
12/2021 FY-0.77--
12/2022 FY-0.62--
Next Report Date29th Apr 2021
Estimated EPS Next Report-0.21
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume5.65M
Shares Outstanding42.26M
Trades Count9.46K
Dollar Volume2.53M
Avg. Volume2.70M
Avg. Weekly Volume6.48M
Avg. Monthly Volume7.61M
Avg. Quarterly Volume2.90M

Idera Pharmaceuticals Inc. (NASDAQ: IDRA) stock closed at 1.34 per share at the end of the most recent trading day (a -0.74% change compared to the prior day closing price) with a volume of 5.83M shares and market capitalization of 56.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Idera Pharmaceuticals Inc. CEO is Vincent J. Milano.

The one-year performance of Idera Pharmaceuticals Inc. stock is -6.64%, while year-to-date (YTD) performance is -63.49%. IDRA stock has a five-year performance of -91.23%. Its 52-week range is between 1.22 and 6.14, which gives IDRA stock a 52-week price range ratio of 2.44%

Idera Pharmaceuticals Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 1.29, a price-to-sale (PS) ratio of 41.75, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -239.45%, a ROC of -2 455.27% and a ROE of 218.06%. The company’s profit margin is -%, its EBITDA margin is -4 027.10%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Idera Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Idera Pharmaceuticals Inc.’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for Idera Pharmaceuticals Inc. is Strong Buy (1), with a target price of $1.5, which is +11.94% compared to the current price. The earnings rating for Idera Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Idera Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Idera Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.24, ATR14 : 0.56, CCI20 : 18.07, Chaikin Money Flow : -0.13, MACD : -0.10, Money Flow Index : 35.30, ROC : 5.73, RSI : 49.86, STOCH (14,3) : 63.53, STOCH RSI : 0.73, UO : 51.96, Williams %R : -36.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Idera Pharmaceuticals Inc. in the last 12-months were: Bryant D. Lim (Sold 10 806 shares of value $23 301 ), Daniel B. Soland (Buy at a value of $38 950), Elizabeth Ann Tarka (Sold 6 763 shares of value $14 088 ), John J. Kirby (Sold 8 805 shares of value $19 389 ), Vincent J. Milano (Sold 43 119 shares of value $184 700 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Idera Pharmaceuticals Inc.

Idera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for oncology and rare diseases. The company has developed two distinct proprietary drug-discovery technology platforms: Toll-like receptor and third-generation antisense technology. The Toll-like receptor technology helped the company create synthetic oligonucleotide-based drug candidates.

CEO: Vincent J. Milano

Telephone: +1 484 348-1600

Address: 505 Eagleview Boulevard, Exton 19341, PA, US

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

45%55%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

News

Stocktwits